Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT03298178
Active, not recruiting Observational

ASAN Medical Center Aortic Valve Replacement Registry

NCT03298178 · tracked via the Priya Life Science South Korea tracker
Sponsor
Ho-Jin Kim
Phase
Observational
Started
2017-12-01
Last updated
2026-01-02

Condition(s) studied

Aortic Valve Stenosis

Investigational drug(s) / intervention(s)

TAVRSAVR

TAVR: All patients who underwent transcatheter aortic valve replacement in Asan medical center, republic of Korea

SAVR: All patients who underwent surgical aortic valve replacement in Asan medical center, republic of Korea

Study summary

This study evaluates the effectiveness and safety of surgical aortic valve replacement and transcatheter aortic valve replacement in aortic Stenosis.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * All successful transcatheter aortic valve replacement or surgical aortic valve replacement * Written consent Exclusion Criteria * Infective endocarditis

Primary outcome measure(s)

  • All cause death — 1 year

Trial sites (1)

FacilityCityRegionStatus
Asan Medical Hospital Seoul South Korea

Other trials for the same condition

CHATEAU Registry: Clinical Outcomes After Transcatheter Aortic Valve Replacement Recruiting
Korea VHD Echo Study: Surveillance of Aortic, Mitral & Tricuspid Patients - Insights From Real-world Practice Starting soon
Lipoprotein(a) and Progression of Aortic Stenosis Active, not recruiting
Evaluation of Effectiveness and Safety of Aortic Valve Replacement in Routine Clinical Practice Active, not recruiting
ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03298178 on ClinicalTrials.gov ↗ ← All trials in South Korea